ESSA Pharma (NASDAQ:EPIX) Releases Earnings Results, Misses Estimates By $0.01 EPS

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) issued its quarterly earnings data on Tuesday. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01), Zacks reports.

ESSA Pharma Stock Performance

Shares of EPIX opened at $1.67 on Thursday. The company has a 50-day moving average price of $1.72 and a two-hundred day moving average price of $3.64. ESSA Pharma has a 12 month low of $1.40 and a 12 month high of $10.25.

Analysts Set New Price Targets

Several research analysts have commented on EPIX shares. Jefferies Financial Group downgraded ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Piper Sandler downgraded shares of ESSA Pharma from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $15.00 to $2.00 in a report on Monday, November 4th. Finally, Oppenheimer lowered ESSA Pharma from an “outperform” rating to a “market perform” rating in a research note on Monday, November 4th.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.